These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38746903)

  • 1. A Tiny Pocket Packs a Punch: Leveraging Pyridones for the Discovery of CNS-Penetrant Aza-indazole IRAK4 Inhibitors.
    Bolduc PN; Pfaffenbach M; Evans R; Xin Z; Henry KL; Gao F; Fang T; Silbereis J; Vera Rebollar J; Li P; Chodaparambil JV; Metrick C; Peterson EA
    ACS Med Chem Lett; 2024 May; 15(5):714-721. PubMed ID: 38746903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-
    Evans R; Bolduc PN; Pfaffenbach M; Gao F; May-Dracka T; Fang T; Hopkins BT; Chodaparambil JV; Henry KL; Li P; Metrick C; Nelson A; Trapa P; Thomas A; Burkly L; Peterson EA
    J Med Chem; 2024 Mar; 67(6):4676-4690. PubMed ID: 38467640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1
    Candito DA; Simov V; Gulati A; Kattar S; Chau RW; Lapointe BT; Methot JL; DeMong DE; Graham TH; Kurukulasuriya R; Keylor MH; Tong L; Morriello GJ; Acton JJ; Pio B; Liu W; Scott JD; Ardolino MJ; Martinot TA; Maddess ML; Yan X; Gunaydin H; Palte RL; McMinn SE; Nogle L; Yu H; Minnihan EC; Lesburg CA; Liu P; Su J; Hegde LG; Moy LY; Woodhouse JD; Faltus R; Xiong T; Ciaccio P; Piesvaux JA; Otte KM; Kennedy ME; Bennett DJ; DiMauro EF; Fell MJ; Neelamkavil S; Wood HB; Fuller PH; Ellis JM
    J Med Chem; 2022 Dec; 65(24):16801-16817. PubMed ID: 36475697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation.
    Pfaffenbach M; Bolduc PN; Xin Z; Gao F; Evans R; Fang T; Chodaparambil JV; Henry KL; Li P; Mathieu S; Metrick C; Vera Rebollar JA; Gu RF; Mccarl CA; Silbereis J; Peterson EA
    J Med Chem; 2024 May; 67(10):8383-8395. PubMed ID: 38695469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors.
    Tzvetkov NT; Stammler HG; Neumann B; Hristova S; Antonov L; Gastreich M
    Eur J Med Chem; 2017 Feb; 127():470-492. PubMed ID: 28107736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.
    Burch JD; Lau K; Barker JJ; Brookfield F; Chen Y; Chen Y; Eigenbrot C; Ellebrandt C; Ismaili MH; Johnson A; Kordt D; MacKinnon CH; McEwan PA; Ortwine DF; Stein DB; Wang X; Winkler D; Yuen PW; Zhang Y; Zarrin AA; Pei Z
    J Med Chem; 2014 Jul; 57(13):5714-27. PubMed ID: 24918870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
    Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L
    Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Feng Y; Park H; Ryu JC; Yoon SO
    ACS Med Chem Lett; 2021 Oct; 12(10):1546-1552. PubMed ID: 34676036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of IRAK4 Inhibitors
    Bothe U; Günther J; Nubbemeyer R; Siebeneicher H; Ring S; Bömer U; Peters M; Rausch A; Denner K; Himmel H; Sutter A; Terebesi I; Lange M; Wengner AM; Guimond N; Thaler T; Platzek J; Eberspächer U; Schäfer M; Steuber H; Zollner TM; Steinmeyer A; Schmidt N
    J Med Chem; 2024 Jan; 67(2):1225-1242. PubMed ID: 38228402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain.
    Shirahashi H; Toriihara E; Suenaga Y; Yoshida H; Akaogi K; Endou Y; Wakabayashi M; Takashima M
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2320-2326. PubMed ID: 31235262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.
    Chen Y; Ning Y; Chen Z; Xue Y; Wu Q; Duan W; Ding J; Zhou J; Xie H; Zhang H
    Eur J Med Chem; 2023 Aug; 256():115453. PubMed ID: 37163947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
    Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
    Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors.
    Hao Y; Ma J; Wang J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
    Eur J Med Chem; 2023 Oct; 258():115616. PubMed ID: 37413880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, evaluation and optimization of potent IRAK4 inhibitors alleviating production of inflammatory cytokines in LPS-induced SIRS model.
    Hao Y; Wang J; Ma J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
    Bioorg Chem; 2023 Aug; 137():106584. PubMed ID: 37163814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of
    Zhang H; Lapointe BT; Anthony N; Azevedo R; Cals J; Correll CC; Daniels M; Deshmukh S; van Eenenaam H; Ferguson H; Hegde LG; Karstens WJ; Maclean J; Miller JR; Moy LY; Simov V; Nagpal S; Oubrie A; Palte RL; Parthasarathy G; Sciammetta N; van der Stelt M; Woodhouse JD; Trotter BW; Barr K
    ACS Med Chem Lett; 2020 Feb; 11(2):114-119. PubMed ID: 32071676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.
    Xu H; Lu H; Xu Z; Luan L; Li C; Xu Y; Dong K; Zhang J; Li X; Li Y; Liu G; Gong S; Zhao YG; Liu A; Zhang Y; Zhang W; Cai X; Xiang JN; Elliott JD; Lin X
    ACS Med Chem Lett; 2016 Apr; 7(4):397-402. PubMed ID: 27096048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of selective COX-2 inhibitors in the (aza)indazole series. Chemistry, in vitro studies, radiochemistry and evaluations in rats of a [
    Elie J; Vercouillie J; Arlicot N; Lemaire L; Bidault R; Bodard S; Hosselet C; Deloye JB; Chalon S; Emond P; Guilloteau D; Buron F; Routier S
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1-7. PubMed ID: 30362376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of (Aza)fulvenallene, Cyanocyclopentadiene, and (Aza)fluorenes in the Thermal Rearrangements of Indazoles, Azaindazoles, and Homoquinolinic Anhydride.
    Mirzaei MS; Wentrup C
    J Org Chem; 2024 Jan; 89(1):553-564. PubMed ID: 38085550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease.
    Kattar SD; Gulati A; Margrey KA; Keylor MH; Ardolino M; Yan X; Johnson R; Palte RL; McMinn SE; Nogle L; Su J; Xiao D; Piesvaux J; Lee S; Hegde LG; Woodhouse JD; Faltus R; Moy LY; Xiong T; Ciaccio PJ; Pearson K; Patel M; Otte KM; Leyns CEG; Kennedy ME; Bennett DJ; DiMauro EF; Fell MJ; Fuller PH
    J Med Chem; 2023 Nov; 66(21):14912-14927. PubMed ID: 37861679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1.
    Cheruvallath Z; Tang M; McBride C; Komandla M; Miura J; Ton-Nu T; Erikson P; Feng J; Farrell P; Lawson JD; Vanderpool D; Wu Y; Dougan DR; Plonowski A; Holub C; Larson C
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2774-2778. PubMed ID: 27155900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.